ATE524190T1 - Hemmung von cholera-toxinen durch galatooligosacchariden (gos) - Google Patents
Hemmung von cholera-toxinen durch galatooligosacchariden (gos)Info
- Publication number
- ATE524190T1 ATE524190T1 AT07834613T AT07834613T ATE524190T1 AT E524190 T1 ATE524190 T1 AT E524190T1 AT 07834613 T AT07834613 T AT 07834613T AT 07834613 T AT07834613 T AT 07834613T AT E524190 T1 ATE524190 T1 AT E524190T1
- Authority
- AT
- Austria
- Prior art keywords
- gos
- galatooligosaccharides
- inhibition
- nutritional
- cholera toxin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06076810 | 2006-10-02 | ||
PCT/NL2007/050475 WO2008041843A1 (en) | 2006-10-02 | 2007-10-01 | Inhibition of cholera toxins by galatooligosaccharides (gos) |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE524190T1 true ATE524190T1 (de) | 2011-09-15 |
Family
ID=37533486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07834613T ATE524190T1 (de) | 2006-10-02 | 2007-10-01 | Hemmung von cholera-toxinen durch galatooligosacchariden (gos) |
Country Status (10)
Country | Link |
---|---|
US (1) | US8202842B2 (de) |
EP (1) | EP2076271B1 (de) |
JP (1) | JP2010505822A (de) |
AT (1) | ATE524190T1 (de) |
DK (1) | DK2076271T3 (de) |
ES (1) | ES2373592T3 (de) |
PL (1) | PL2076271T3 (de) |
PT (1) | PT2076271E (de) |
SI (1) | SI2076271T1 (de) |
WO (1) | WO2008041843A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080126195A1 (en) | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
FR2907687B1 (fr) * | 2006-10-30 | 2008-12-26 | Applexion | Procede de purification de sialyllactose par chromatographie |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
GB2480042B (en) | 2009-02-24 | 2014-03-12 | Ritter Pharmaceuticals Inc | Solid oral unit-dosage prebiotic forms and methods of use |
US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
AU2010223965A1 (en) * | 2009-03-13 | 2011-10-06 | Dsm Food Specialties Usa Inc. | Prebiotic oligosaccharides |
US20110189342A1 (en) * | 2010-02-01 | 2011-08-04 | Jeong Hea-Seok | High-purity galactooligosaccharides and uses thereof |
NL2007931C2 (en) * | 2011-12-07 | 2013-06-10 | Friesland Brands Bv | Methods for providing sialylated oligosaccharides and products obtainable thereby. |
US10695358B2 (en) | 2013-12-20 | 2020-06-30 | Abbott Laboratories | Oral rehydration composition with oligosaccharides |
EP3530743A1 (de) | 2018-02-21 | 2019-08-28 | Cambridge Glycoscience Ltd | Verfahren zur herstellung |
CN113163828B (zh) | 2018-08-15 | 2024-04-26 | 剑桥糖质科学有限公司 | 新型组合物、其用途及其形成方法 |
EP3846641A1 (de) | 2018-09-06 | 2021-07-14 | FrieslandCampina Nederland B.V. | Bifidogene hypoallergene gos-zusammensetzungen und verfahren zu ihrer herstellung mit beta-galactosidase aus einem stamm von lactobacillus delbrueckii ssp bulgaricus |
AU2019376668A1 (en) * | 2018-11-08 | 2021-05-13 | Dsm Ip Assets, B.V. | Methods of selectively modulating gastrointestinal microbial growth |
MX2021005379A (es) * | 2018-11-08 | 2021-09-14 | Dsm Ip Assets Bv | Metodos para modular metabolitos gastrointestinales. |
JP2022545650A (ja) | 2019-08-16 | 2022-10-28 | ケンブリッジ グリコサイエンス エルティーディー | バイオマスを処理してオリゴ糖および関連組成物を生成する方法 |
EP4072318A2 (de) | 2019-12-12 | 2022-10-19 | Cambridge Glycoscience Ltd | Mehrphasige lebensmittel mit niedrigem zuckergehalt |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0614870B2 (ja) * | 1986-12-15 | 1994-03-02 | 株式会社ヤクルト本社 | ガラクトオリゴ糖の製造法 |
NZ222902A (en) | 1986-12-15 | 1990-08-28 | Yakult Honsha Kk | Method for producing galactooligosaccharide |
ZA991410B (en) * | 1998-02-23 | 1999-10-06 | Synsorb Biotech Inc | Compounds and methods for the treatment of bacterial dysentry using antibiotics and toxin binding oligosaccharide compositions. |
US6630452B2 (en) * | 2000-02-17 | 2003-10-07 | Wyeth | Nutritional formulation containing prebiotic substances |
FR2838452B1 (fr) | 2002-04-10 | 2004-07-09 | Eurodia Ind | Procede de production en continu de galacto oligosaccharides |
GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
GB0308104D0 (en) | 2003-04-08 | 2003-05-14 | Novartis Nutrition Ag | Organic compounds |
MXPA05010349A (es) | 2003-06-30 | 2006-03-08 | Clasado Inc | Composicion novedosa de galactooligosacaridos y preparacion de la misma. |
EP1641581B1 (de) | 2003-07-04 | 2020-02-26 | Commonwealth Scientific And Industrial Research Organisation | Verfahren zur herstellung von metallverbindungen |
ATE412767T1 (de) * | 2003-10-02 | 2008-11-15 | Nestec Sa | Präbiotische effektanalyse |
-
2007
- 2007-10-01 PL PL07834613T patent/PL2076271T3/pl unknown
- 2007-10-01 EP EP07834613A patent/EP2076271B1/de not_active Not-in-force
- 2007-10-01 US US12/443,565 patent/US8202842B2/en not_active Expired - Fee Related
- 2007-10-01 DK DK07834613.7T patent/DK2076271T3/da active
- 2007-10-01 AT AT07834613T patent/ATE524190T1/de not_active IP Right Cessation
- 2007-10-01 PT PT07834613T patent/PT2076271E/pt unknown
- 2007-10-01 ES ES07834613T patent/ES2373592T3/es active Active
- 2007-10-01 SI SI200730768T patent/SI2076271T1/sl unknown
- 2007-10-01 WO PCT/NL2007/050475 patent/WO2008041843A1/en active Application Filing
- 2007-10-01 JP JP2009531332A patent/JP2010505822A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2008041843A1 (en) | 2008-04-10 |
US20100069322A1 (en) | 2010-03-18 |
PL2076271T3 (pl) | 2012-02-29 |
JP2010505822A (ja) | 2010-02-25 |
US8202842B2 (en) | 2012-06-19 |
DK2076271T3 (da) | 2012-01-16 |
SI2076271T1 (sl) | 2011-12-30 |
PT2076271E (pt) | 2011-12-02 |
EP2076271A1 (de) | 2009-07-08 |
ES2373592T3 (es) | 2012-02-06 |
EP2076271B1 (de) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE524190T1 (de) | Hemmung von cholera-toxinen durch galatooligosacchariden (gos) | |
WO2004103294A3 (en) | Methods and compositions for the prevention and treatment of sepsis | |
BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
MY169746A (en) | Dual variable domain immunoglobulin and uses thereof | |
ATE375164T1 (de) | Endotoxin-bindung durch milchsäurebakterien und bifidobacteria | |
WO2006128032A3 (en) | Compositions and methods for the prevention and treatment of conditions associated with inflammation | |
WO2008024188A8 (en) | Dual variable domain immunoglobulin and uses thereof | |
BRPI0924058A2 (pt) | anticorpos contra inibidor da via de fator tecidual | |
BRPI0616960B8 (pt) | uso de lactobacilo para o tratamento de infecções virais | |
MX2009000657A (es) | Composiciones y metodos para el tratamiento de mucositis. | |
WO2008036932A3 (en) | Compositions and methods comprising boswellia species | |
ATE537819T1 (de) | Nutrazeutische zusammensetzungen zur behandlung von muskelschwund | |
WO2007103114A3 (en) | Notch inhibition in the treatment or prevention of atherosclerosis | |
MX2008000064A (es) | Metodos y composiciones para el tratamiento de condiciones oftalmicas via retinol de suero, proteina de enlace de retinol de suero (rbp) y/o modulacion de retinol-rbp del suero. | |
WO2007059154A3 (en) | Treatment of cancers with acquired resistance to kit inhibitors | |
BRPI0722054A2 (pt) | Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico. | |
WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
WO2008008772A3 (en) | Methods for treating and limiting fibrotic disorders and keloids | |
WO2007100765A3 (en) | Lysozyme-modified probiotic components and uses thereof | |
ATE473277T1 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten | |
DK2208734T3 (da) | Levnedsmiddelmateriale til inhibering af dannelsen af osteoclast | |
EP2500354A3 (de) | Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung | |
DE602004005455D1 (de) | Verfahren zur behandlung oder prävention von chronischen wunden und komplette nahrungszusammensetzung mit glycin und/oder leucin zur verwendung darin | |
WO2008063853A3 (en) | Cancer treatment method | |
EA201200182A1 (ru) | Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |